Celgene Ducks Teva Unit's Breast-Cancer Drug IP Claims
A Massachusetts federal judge entered an order Tuesday clearing Celgene Corp. of allegations that its antitumor drug Abraxane infringed a Teva Pharmaceutical Industries Ltd. unit's patent covering the drug's active ingredient,...To view the full article, register now.
Already a subscriber? Click here to view full article